Quick Answer
India's GLP-1 market has reached Rs 1,906 crore (MAT May 2026) — up 237% year-on-year. Tirzepatide leads at 63% share. Generic semaglutide now starts at Rs 325 per weekly injection, making treatment far more accessible for Indian patients.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
India's anti-obesity and diabetes drug market has crossed a landmark threshold. The GLP-1 receptor agonist segment — the category that includes Ozempic, Wegovy, and Mounjaro — has grown to nearly Rs 2,000 crore on a moving annual turnover basis as of May 2026, registering a 237 percent jump over the previous year. For Indian patients watching GLP-1 drugs transform global healthcare, these numbers confirm a simple truth: the revolution has arrived in India, and it is already driving down prices and widening access.
How Big India's GLP-1 Market Has Become
According to pharmaceutical market data published in June 2026, India's GLP-1 market reached Rs 1,906 crore on a moving annual turnover basis through May 2026. Just a year and a half ago, this category was a niche segment. Today it is one of the most closely watched growth areas in Indian pharma, and the growth rate of 237 percent makes India one of the fastest-expanding GLP-1 markets in the world.
Two molecules dominate almost entirely. Tirzepatide — the active ingredient in Mounjaro and Zepbound, made by Eli Lilly — accounts for 63 percent of total GLP-1 market value, with sales of Rs 1,207 crore. Semaglutide — the active ingredient in Ozempic and Wegovy, made by Novo Nordisk — contributes Rs 589 crore and holds a 31 percent market share. Together, the two blockbuster molecules account for nearly 94 percent of the entire GLP-1 market in India.
Why Tirzepatide Is Pulling Further Ahead
After a period when the launch of generic semaglutide created pricing pressure across the GLP-1 category, tirzepatide has returned strongly to growth. Monthly tirzepatide sales rose from Rs 121 crore in April 2026 to Rs 136 crore in May 2026, and unit volumes climbed from 93,000 to 104,000 units in the same period — growth of more than 10 percent in a single month.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The reason is clinical. Tirzepatide is a dual-agonist drug that activates both GLP-1 and GIP receptors simultaneously — two complementary hormonal pathways that together produce more powerful results than either pathway alone. In the landmark SURMOUNT-5 head-to-head trial, tirzepatide produced approximately 20 percent body weight reduction compared to around 14 percent for semaglutide over 72 weeks. As more Indian patients and doctors have become aware of these head-to-head results, and as patients who plateaued on semaglutide look for stronger options, the market has been shifting toward tirzepatide. Patients who have achieved what they can on semaglutide — and want to go further — are increasingly switching.
The Generic Semaglutide Revolution
The semaglutide side of the market tells a different but equally important story. Following the expiry of the original semaglutide patent in early 2026, more than 40 DCGI-approved generic semaglutide brands are now in circulation across India. Generic semaglutide is available from as low as Rs 325 per weekly injection — meaning a full month of treatment can cost as little as Rs 1,300 to Rs 1,600. This compares to Rs 12,000 to Rs 18,000 per month for branded Ozempic less than two years ago.
This price collapse has had two important effects. First, it has brought GLP-1 therapy within genuine reach of a much larger group of Indian patients. People who could never have afforded branded Ozempic are now starting semaglutide at prices that compete with many standard diabetes medications. Second, the wide availability of affordable semaglutide has clarified the market: patients who need more than semaglutide can achieve are now identifiable, and they are moving toward tirzepatide.
The pace of new semaglutide patients entering the market has slowed somewhat — consistent with a pattern seen after any major drug goes generic, as the backlog of previously underserved patients gets served relatively quickly. But this slowdown reflects market maturation, not diminishing clinical need. India has 77 million people living with type 2 diabetes and hundreds of millions more carrying excess weight at metabolic risk. The addressable patient population remains enormous.
What This Means for Indian Patients Today
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you have been waiting for affordable GLP-1 access, the moment has arrived. Generic semaglutide is available now across Indian pharmacies with a valid prescription, and the price is genuinely accessible. With over 40 DCGI-approved brands in circulation, a GLP-1 specialist can help you identify a reputable supplier and set up a proper dose escalation schedule to minimise nausea and side effects.
If you tried semaglutide and found the weight loss results inadequate or if you have plateaued after initial success, tirzepatide is available in India as branded Mounjaro. At current prices of Rs 20,000 to Rs 35,000 per month depending on dose, it is significantly more expensive than generic semaglutide. But for patients with significant obesity — a body mass index above 35, for instance — the additional efficacy often justifies the difference. Generic tirzepatide is not yet available in India but pharmaceutical market analysts expect domestic manufacturers to launch competitive versions as patent protections expire in the Indian market, potentially as soon as 2027. When that happens, India's most powerful weight-loss drug could become as affordable as semaglutide is today.
For patients with type 2 diabetes, both drugs reduce HbA1c effectively alongside their weight loss benefits. The GLP-1 mechanism is particularly well matched to Indian patients, who tend to have more severe insulin resistance relative to body weight than Western populations. Both drugs address insulin resistance directly rather than simply stimulating more insulin secretion — meaning a lower risk of hypoglycemia and metabolic benefits that go well beyond blood sugar control.
The bottom line from the market data is this: India's GLP-1 story is not a trend that is building slowly. It is already a Rs 2,000 crore reality growing at 237 percent per year. The drugs are available, the prices are falling, and the clinical evidence base is among the strongest in modern medicine. If you or a family member is living with obesity or type 2 diabetes, now is a genuinely good time to have an informed conversation with a specialist.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Medical Dialogues — India's GLP-1 Market Nears Rs 2,000 Crore as Semaglutide Boom Slows, Tirzepatide Regains Momentum — https://medicaldialogues.in/news/industry/pharma/indias-glp-1-market-nears-rs-2000-crore-as-semaglutide-boom-slows-tirzepatide-regains-momentum-173338 2. BioSpectrum India — GLP-1 market nears Rs 2,000 Cr in MAT May 2026 as Tirzepatide and Semaglutide dominate segment — https://www.biospectrumindia.com/news/73/27946/glp-1-market-nears-rs-2000-cr-in-mat-may-2026-as-tirzepatide-and-semaglutide-dominate-segment-sheetal-sapale.html 3. DermaVue — Generic Semaglutide India 2026: Brands, Prices, Cost — https://dermavue.com/medical-weight-loss/generic-glp1-india/
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.